Compare Merck & Co., Inc. (MRK) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Tripadvisor Inc Common Stock — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while Tripadvisor Inc Common Stock trades at $8.77 (market cap $1.07B). The key difference: Merck & Co., Inc. is far larger — about 342.3× Tripadvisor Inc Common Stock's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| MRK | TRIP | |
|---|---|---|
Market Cap | $366.28B | $1.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $19.14 |
52-Week Low | $77.60 | $8.82 |
Enterprise Value | $413.04B | $1.12B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Tripadvisor (TRIP) trades at $9.085, down 2.57% for the day, reflecting ongoing pressure from recent earnings misses and competitive challenges. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong gross margins (92.11%) but thin net income (0.27%). Recent news highlights insider selling and TheFork subsidiary sale, creating uncertainty about growth prospects amid AI-driven travel competition.
The outlook remains cautious with analyst consensus leaning Hold (62.5%) despite a $11.80 price target suggesting 30% upside. Key risks include persistent earnings volatility, market share erosion to AI platforms, and declining cash flow trends. Investment opportunity hinges on Viator's performance and successful execution of strategic initiatives post-TheFork divestiture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
